Read more
12:07 PM · 10 May 2024

Novavax shares gain 120% after announcing licensing agreement with Sanofi 🚨

-
-
Open account Download free app
-
-
Open account Download free app

Novavax (NVAX.US) shares are gaining nearly 120% before the start of this week's final trading session on the back of the signing of a $1.2 billion licensing agreement with Sanofi (SAN.FR).

Current stock price change before the opening of the Wall Street session. Source: Yahoo Finance

Under the deal, Sanofi will acquire a 4.9% stake in the U.S. drugmaker. The taj deal and the stake acquisition values Novavax at about $1.4 billion, almost double its market capitalization of about $628 million yesterday.  The agreement entitles Novavax to an upfront cash payment of $500 million and future payments contingent on certain milestones, as well as royalties ($700 million).

On the other hand, Sanofi will be licensed to co-market Novavax's vaccine in most countries and to use this COVID vaccine together with its own influenza vaccines as a combination vaccine. The license will begin early in the new year. Sanofi will also benefit from Novavax's flagship vaccine technology, the Matrix-M adjuvant, which can be used to develop entirely new vaccines. Novavax could gain another $200 million in this utility, the company added in a public announcement.

More details of this agreement can be found at the link below

Source: xStation 

6 February 2026, 2:09 PM

Kongsberg Gruppen after earnings: The company catches up with the sector

6 February 2026, 1:20 PM

Market wrap: European indices attempt a rebound after Wall Street’s record selloff 🔨

6 February 2026, 6:56 AM

Morning wrap: Tech sector sell-off (06.02.2026)

5 February 2026, 9:38 PM

Amazon shares tumble 10% as investors recoil at the price of AI dominance

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits